KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Land & Improvements (2014 - 2016)

Jazz Pharmaceuticals' quarterly Land & Improvements came in at $1.8 million in Q1 2016, up 33.19% year-on-year from $1.4 million in Q2 2015, and up 3.55% quarter-over-quarter from $1.8 million in Q4 2015.

Jazz Pharmaceuticals has reported Land & Improvements for 3 years, with the latest figure at $1.8 million in Q1 2016.

  • For the quarter ending Q1 2016, Land & Improvements rose 33.19% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2016 stood at $1.8 million (up 33.19% YoY), and the FY2015 full-year result was $1.8 million, up 14.74% from the prior year.
  • Land & Improvements for Q1 2016 stood at $1.8 million, up from $1.8 million in the prior quarter.
  • The five-year high for Land & Improvements was $1.8 million in Q1 2016, with the low at $1.4 million in Q1 2015.
  • Average Land & Improvements over 3 years is $1.7 million, with a median of $1.7 million recorded in 2014.
  • Year-over-year, Land & Improvements dropped 17.76% in 2015 and jumped 33.19% in 2016.
  • Tracing JAZZ's Land & Improvements over 3 years: stood at $1.5 million in 2014, then advanced by 14.74% to $1.8 million in 2015, then advanced by 3.55% to $1.8 million in 2016.
  • The last three Land & Improvements figures came in at $1.8 million (Q1 2016), $1.8 million (Q4 2015), and $1.8 million (Q3 2015), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Land & Improvements (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Jazz Pharmaceuticals 14.35 Bn 12.51 Bn 934.80 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2016 1.84 Mn
Dec 31, 2015 1.78 Mn
Sep 30, 2015 1.78 Mn
Jun 30, 2015 1.69 Mn
Mar 31, 2015 1.38 Mn
Dec 31, 2014 1.55 Mn
Sep 30, 2014 1.61 Mn
Jun 30, 2014 1.69 Mn
Mar 31, 2014 1.68 Mn